StockData
Bicycle Therapeutics PLC logo

Bicycle Therapeutics PLC (BCYC) shareholders

BCYCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 11/3080% below fair value
$3.20+0.02 (+0.63%)

Close on Nov 17, 2026Market cap $224.30MP/E –Yield 0.00%

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
53.4%
37M of 70M shares
Institutional holders
104
19 new, 13 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 49 sales
Net sold $522.73K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Felix J. Baker
Joint filing with Baker Bros. Advisors LP (22.90%), Baker Bros. Advisors (GP) LLC (22.90%) and 1 more
10,885,35722.90%13D (active) amendmentDec 13, 2024
Point72 Capital Advisors, Inc.
Joint filing with Point72 Asset Management, L.P. (8.90%), Steven A. Cohen (8.90%)
4,230,3028.90%13G (passive)Dec 13, 2024
Steven A. Cohen
Joint filing with Point72 Asset Management, L.P. (7.80%), Point72 Capital Advisors, Inc. (7.80%)
3,739,3187.80%13G (passive) amendmentMar 31, 2025
Forbion Growth Ii Management B.V.
Joint filing with Forbion Growth Opportunities Fund II Cooperatief U.A. (7.30%)
3,452,3307.30%13G (passive)Nov 21, 2024
Armistice Capital, LLC
Joint filing with Steven Boyd (6.75%)
3,398,0006.75%13G (passive) amendmentMar 31, 2026
Steven Boyd
Joint filing with Armistice Capital, LLC (6.72%)
3,398,0006.72%13G (passive) amendmentJun 30, 2026
John Helmers
Joint filing with Long Focus Capital Management, LLC (6.60%)
3,310,6876.60%13G (passive)Mar 31, 2026
David Kroin
Joint filing with Deep Track Capital, LP (5.67%), Deep Track Biotechnology Master Fund, Ltd. (5.67%)
2,821,1715.67%13G (passive) amendmentMar 31, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of BCYCValueChange% of portfolio
Baker Bros. Advisors LP10,885,35715.53%$46.15M–0.23%
Fcpm Iii Services B.V.3,468,4304.95%$14.71M–1.96%
Armistice Capital, LLC3,398,0004.85%$14.41M–0.18%
Long Focus Capital Management, LLC3,310,6874.72%$14.04M–0.36%
Acadian Asset Management LLC1,968,0252.81%$8.32M–0.01%
Renaissance Technologies LLC1,533,4002.19%$6.50M+554,1000.01%
GSK plc1,529,5612.18%$6.49M–1.08%
Price T Rowe Associates Inc /Md/902,1501.29%$3.83M−126,0930.00%
Marshall Wace, Llp797,9401.14%$3.38M+420,6050.00%
Qube Research & Technologies Ltd775,5671.11%$3.29M+466,9500.00%
Morgan Stanley667,2690.95%$2.83M+48,9420.00%
Schroder Investment Management Group615,8330.88%$2.56M–0.00%
Citadel Advisors LLC554,2250.79%$2.35M+177,1400.00%
Millennium Management LLC553,9670.79%$2.35M+269,9810.00%
Peapod Lane Capital LLC537,9780.77%$2.28M+416,8721.54%
Diadema Partners LP462,7240.66%$1.96M−13,7000.25%
Two Sigma Investments, LP434,5770.62%$1.84M+269,7770.00%
Jane Street Group, LLC392,1630.56%$1.66M+174,0480.00%
Flax Pond Capital, LLC376,2220.54%$1.67M+200,0860.62%
Birchview Capital, LP313,6160.45%$1.33M−149,9830.62%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202610437M53.4%19 / 3418 / 134M4M
Q1 20269837M53.4%15 / 4316 / 265M7M
Q4 202510939M55.9%22 / 3529 / 115M3M
Q3 20259937M52.7%10 / 3824 / 213M7M
Q2 202511041M58.8%29 / 3820 / 145M5M
Q1 20259542M59.5%15 / 2830 / 174M4M
Q4 20249742M59.8%16 / 2936 / 2311M10M
Q3 202410540M57.7%17 / 3433 / 186M5M
Q2 202410740M57.5%26 / 3525 / 1416M9M
Q1 20249534M47.9%13 / 2933 / 178M7M
Q4 202310133M47.0%21 / 3730 / 218M7M
Q3 202310132M46.3%24 / 3524 / 710M2M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

26 funds held BCYC in Q1 2026, 12% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of BCYCValue% of fundAs of
T. Rowe Price Health Sciences Fund, Inc.628,4210.90%$2.66M0.02%Jun 30, 2026
Old Westbury Small & Mid Cap Strategies Fund265,9730.38%$1.03M0.01%Jul 31, 2026
iShares Biotechnology ETF242,5770.35%$1.03M0.01%Jun 30, 2026
Virtus Biotech Clinical Trials Etf76,7430.11%$296.23K0.64%Jul 31, 2026
T. Rowe Price Health Sciences Portfolio62,8460.09%$266.47K0.04%Jun 30, 2026
ALPS Medical Breakthroughs ETF51,4500.07%$241.30K0.15%May 31, 2026
State Street(R) SPDR(R) S&P(R) International Small Cap ETF30,8290.04%$130.71K0.02%Jun 30, 2026
Voya Multi-Manager International Small Cap Fund30,0520.04%$116.00K0.02%Jul 31, 2026
Health Sciences Trust25,6020.04%$108.55K0.04%Jun 30, 2026
Fidelity Nasdaq Composite Index Fund25,1290.04%$117.86K0.00%May 31, 2026
Invesco NASDAQ Future Gen 200 ETF13,4100.02%$62.89K0.33%May 31, 2026
Horizon Kinetics Medical ETF12,5840.02%$53.36K0.28%Jun 30, 2026
Steward Values Enhanced International Fund11,2090.02%$43.27K0.01%Jul 31, 2026
EQ/T.Rowe Price Health Sciences Portfolio9,6000.01%$40.70K0.02%Jun 30, 2026
Harbor International Core Fund6,1020.01%$23.55K0.00%Jul 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Kevin LeeCHIEF EXECUTIVE OFFICER, Director595,8660.85%Oct 6, 2026
Jennifer Scott PerryChief Operating Officer89,6020.13%Oct 7, 2026
Michael SkynnerCHIEF SCIENTIFIC OFFICER154,7260.22%Oct 6, 2026
Michael Charles Ferguson HannayCHIEF PROD & SUPPLY CHAIN OFF92,5610.13%Oct 6, 2026
Travis Alvin ThompsonChief Financial Officer64,4490.09%Oct 6, 2026
Alistair MilnesCHIEF OPERATING OFFICER136,7170.20%Jan 6, 2026
Alethia YoungChief Financial Officer88,9590.13%Jan 6, 2026
Eric WestinChief Medical Officer2,3050.00%Mar 27, 2025
Nigel CrockettCHIEF BUSINESS OFFICER51,0530.07%Jan 6, 2025
Santiago ArroyoCHIEF DEVELOPMENT OFFICER69,0570.10%Jan 6, 2025
Robert Charles SwantonDirector15,7820.02%Oct 6, 2026
Roger D. DanseyDirector15,5320.02%Jan 6, 2026
Stephen H. SandsDirector26,8930.04%Jan 6, 2026
Jose-Carlos Gutierrez-RamosDirector32,5000.05%Jan 6, 2026
Bros. Advisors Lp BakerDirector, 10% owner918,4831.31%Jan 6, 2026
Julian BakerDirector, 10% owner––Jan 6, 2026
Felix BakerDirector, 10% owner937,4831.34%Jan 6, 2026
Brothers Life Sciences LP BakerDirector, 10% owner579,8560.83%Jan 6, 2026
Bros. Advisors (GP) LLC BakerDirector, 10% owner9,995,27414.26%Jan 6, 2026
667, L.P.Director, 10% owner787,9541.12%Jan 6, 2026
Herve HoppenotDirector15,5320.02%Jan 6, 2026
Gregory Paul WinterDirector196,4270.28%Jan 6, 2026
Janice BourqueDirector32,5000.05%Jan 6, 2026
Alessandro RivaDirector19,8800.03%Jan 6, 2026
Pierre LegaultDirector46,0000.07%Jan 6, 2025
Richard N. KenderDirector23,0000.03%Jan 6, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Jennifer Scott Perry
Chief Operating Officer
Oct 5, 2026Sale(10b5-1 plan)−326$3.78$1.23K89,602
Jennifer Scott Perry
Chief Operating Officer
Oct 5, 2026Sale(10b5-1 plan)−30$3.57$10789,928
Jennifer Scott Perry
Chief Operating Officer
Oct 5, 2026Sale(10b5-1 plan)−326$3.78$1.23K89,552
Jennifer Scott Perry
Chief Operating Officer
Oct 5, 2026Sale(10b5-1 plan)−80$3.56$28589,878
Michael Charles Ferguson Hannay
CHIEF PROD & SUPPLY CHAIN OFF
Oct 5, 2026Sale−242$3.57$86492,561
Travis Alvin Thompson
Chief Financial Officer
Oct 5, 2026Sale−79$3.57$28264,449
Kevin Lee
CHIEF EXECUTIVE OFFICER, Director
Oct 5, 2026Sale−1,638$3.57$5.85K595,866
Michael Skynner
CHIEF SCIENTIFIC OFFICER
Oct 5, 2026Sale−503$3.57$1.80K154,726
Jennifer Scott Perry
Chief Operating Officer
Oct 2, 2026Sale(10b5-1 plan)−1,094$3.47$3.80K89,958
Robert Charles Swanton
Director
Oct 2, 2026Sale−3,431$3.47$11.91K15,782
Michael Charles Ferguson Hannay
CHIEF PROD & SUPPLY CHAIN OFF
Oct 2, 2026Sale−1,572$3.47$5.45K92,803
Travis Alvin Thompson
Chief Financial Officer
Oct 2, 2026Sale−893$3.47$3.10K64,528
Kevin Lee
CHIEF EXECUTIVE OFFICER, Director
Oct 2, 2026Sale−6,167$3.47$21.40K597,504
Michael Skynner
CHIEF SCIENTIFIC OFFICER
Oct 2, 2026Sale−1,942$3.47$6.74K155,229
Travis Alvin Thompson
Chief Financial Officer
Jul 6, 2026Sale−104$4.31$44864,441
Jennifer Scott Perry
Chief Operating Officer
Jul 6, 2026Sale(10b5-1 plan)−43$4.31$18591,385
Jennifer Scott Perry
Chief Operating Officer
Jul 6, 2026Sale(10b5-1 plan)−333$4.34$1.45K91,052
Kevin Lee
CHIEF EXECUTIVE OFFICER, Director
Jul 6, 2026Sale−1,737$4.31$7.49K603,671
Michael Skynner
CHIEF SCIENTIFIC OFFICER
Jul 6, 2026Sale−532$4.31$2.29K157,171
Michael Charles Ferguson Hannay
CHIEF PROD & SUPPLY CHAIN OFF
Jul 6, 2026Sale−255$4.31$1.10K94,375
Travis Alvin Thompson
Chief Financial Officer
Jul 2, 2026Sale−819$4.27$3.50K64,545
Jennifer Scott Perry
Chief Operating Officer
Jul 2, 2026Sale(10b5-1 plan)−1,036$4.27$4.42K91,428
Kevin Lee
CHIEF EXECUTIVE OFFICER, Director
Jul 2, 2026Sale−5,905$4.27$25.21K605,408
Michael Skynner
CHIEF SCIENTIFIC OFFICER
Jul 2, 2026Sale−1,859$4.27$7.94K157,703
Michael Charles Ferguson Hannay
CHIEF PROD & SUPPLY CHAIN OFF
Jul 2, 2026Sale−1,506$4.27$6.43K94,630
Jennifer Scott Perry
Chief Operating Officer
Apr 6, 2026Sale(10b5-1 plan)−333$5.04$1.68K92,464
Jennifer Scott Perry
Chief Operating Officer
Apr 6, 2026Sale(10b5-1 plan)−37$5.05$18792,797
Michael Skynner
CHIEF SCIENTIFIC OFFICER
Apr 6, 2026Sale−525$5.05$2.65K159,562
Travis Alvin Thompson
Chief Financial Officer
Apr 6, 2026Sale−102$5.05$51565,364
Michael Charles Ferguson Hannay
CHIEF PROD & SUPPLY CHAIN OFF
Apr 6, 2026Sale−251$5.05$1.27K96,136
Kevin Lee
CHIEF EXECUTIVE OFFICER, Director
Apr 6, 2026Sale−1,716$5.05$8.67K611,313
Jennifer Scott Perry
Chief Operating Officer
Apr 2, 2026Sale(10b5-1 plan)−1,038$4.91$5.10K92,834
Michael Skynner
CHIEF SCIENTIFIC OFFICER
Apr 2, 2026Sale−1,879$4.91$9.23K160,087
Travis Alvin Thompson
Chief Financial Officer
Apr 2, 2026Sale−799$4.91$3.92K65,466
Michael Charles Ferguson Hannay
CHIEF PROD & SUPPLY CHAIN OFF
Apr 2, 2026Sale−1,521$4.91$7.47K96,387
Kevin Lee
CHIEF EXECUTIVE OFFICER, Director
Apr 2, 2026Sale−5,967$4.91$29.30K613,029
Kevin Lee
CHIEF EXECUTIVE OFFICER, Director
Jan 5, 2026Sale−10,989$6.46$70.99K618,996
Michael Charles Ferguson Hannay
CHIEF PROD & SUPPLY CHAIN OFF
Jan 5, 2026Sale−2,367$6.45$15.27K97,908
Alethia Young
Chief Financial Officer
Jan 5, 2026Sale(10b5-1 plan)−2,456$6.45$15.84K88,959
Alethia Young
Chief Financial Officer
Jan 5, 2026Sale(10b5-1 plan)−1,878$6.54$12.28K87,081
Alistair Milnes
CHIEF OPERATING OFFICER
Jan 5, 2026Sale−3,416$6.46$22.07K136,717
Michael Skynner
CHIEF TECHNOLOGY OFFICER
Jan 5, 2026Sale−3,266$6.46$21.10K161,966
Travis Alvin Thompson
CHIEF ACCOUNTING OFFICER
Jan 5, 2026Sale−1,115$6.45$7.19K66,265
Alessandro Riva
Director
Jan 2, 2026Award+7,380––19,880
Kevin Lee
CHIEF EXECUTIVE OFFICER, Director
Jan 2, 2026Award+165,000––640,310
Kevin Lee
CHIEF EXECUTIVE OFFICER, Director
Jan 2, 2026Sale−10,325$6.80$70.21K629,985
Michael Charles Ferguson Hannay
CHIEF PROD & SUPPLY CHAIN OFF
Jan 2, 2026Sale−2,827$6.80$19.22K100,275
Michael Charles Ferguson Hannay
CHIEF PROD & SUPPLY CHAIN OFF
Jan 2, 2026Award+50,000––103,102
Alethia Young
Chief Financial Officer
Jan 2, 2026Award+50,000––94,704
Alethia Young
Chief Financial Officer
Jan 2, 2026Sale(10b5-1 plan)−3,289$6.80$22.37K91,415
Roger D. Dansey
Director
Jan 2, 2026Award+3,032––15,532
Jose-Carlos Gutierrez-Ramos
Director
Jan 2, 2026Award+9,500––32,500
Stephen H. Sands
Director
Jan 2, 2026Award+9,500––26,893
Janice Bourque
Director
Jan 2, 2026Award+9,500––32,500
Alistair Milnes
CHIEF OPERATING OFFICER
Jan 2, 2026Award+50,000––143,377
Alistair Milnes
CHIEF OPERATING OFFICER
Jan 2, 2026Sale−3,244$6.80$22.06K140,133
Herve Hoppenot
Director
Jan 2, 2026Award+3,032––15,532
Felix Baker
Director, 10% owner
Jan 2, 2026Award+19,000––937,483
Felix Baker
Director, 10% owner
Jan 2, 2026Award+19,000––10,018,674
Michael Skynner
CHIEF TECHNOLOGY OFFICER
Jan 2, 2026Award+50,000––168,277

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
–
4M shares short
Days to cover
8.4
At 0M shares a day
Change since last report
+11.7%
From 3M shares
Short volume, 20 days
53.7%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Bicycle Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 17,319 shares on Oct 7, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Kevin Lee
Officer
Oct 2, 20269,000$31.23KOct 2, 2026Restricted Stock Units
Kevin Lee
Officer
Jul 2, 20268,000$34.16KJul 2, 2026Restricted Stock Units
Kevin Lee
Officer
Apr 2, 20268,000$39.24KApr 2, 2026Restricted Stock
Michael Skynner
Officer
Apr 2, 20262,500$12.26KApr 2, 2026Restricted Stock
Alistair Milnes
Officer
Apr 2, 20262,850$13.98KApr 2, 2026Restricted Stock
Michael Charles Ferguson Hannay
Officer
Apr 2, 20261,850$9.07KApr 2, 2026Restricted Stock
Travis Alvin Thompson
Officer
Apr 2, 20261,000$4.91KApr 2, 2026Restricted Stock
Alethia Young
Officer
Apr 2, 20262,034$9.98KApr 2, 2026Restricted Stock
Jennifer Scott Perry
Officer
Apr 2, 20261,500$7.36KApr 2, 2026Restricted Stock
Alethia Young
Officer
Jan 5, 2026123$803Jan 5, 2026Restricted Stock Units
Michael Skynner
Officer
Jan 2, 20266,400$43.51KJan 2, 2026Restricted Stock Units
Alistair Milnes
Officer
Jan 2, 20266,750$46.85KJan 2, 2026Restricted Stock Units
Kevin Lee
Officer
Jan 2, 202621,500$146.16KJan 2, 2026Restricted Stock Units
Michael Charles Ferguson Hannay
Officer
Jan 2, 20265,250$35.69KJan 2, 2026Restricted Stock Units
Alethia Young
Officer
Jan 2, 20267,500$50.99KJan 2, 2026Restricted Stock Units

See a number that looks wrong?